ANTI-PD-L1 NANOBODY AND USE THEREOF

WIPO Patent Application WO/2023/011614

A1

Provided are an anti-PD-L1 nanobody and the use thereof. The anti-PD-L1 nanobody contains CDR1, CDR2 and CDR3, wherein CDR1 contains a sequence selected from SEQ ID NOs: 1, 5 and 9, CDR2 contains a sequence selected from SEQ ID NOs: 2, 6 and 10, and CDR3 contains a sequence selected from SEQ ID NOs: 3, 7, 11 and 14. The antibody can block signaling pathways of PD-1/PD-L1 and CD-80/PD-L1, inhibit the growth of tumor cells, and exhibit a tumor treatment effect.

JP2011121954	IDENTIFICATION AND ENGINEERING OF ANTIBODY WITH VARIANT Fc REGION AND METHOD FOR UTILIZING THE SAME
JP2008507499	Combination anti-cancer therapy and its pharmaceutical composition
WO/2018/217227	NOVEL ANTI-PD-1 CHECKPOINT INHIBITOR ANTIBODIES THAT BLOCK BINDING OF PD-L1 TO PD-1

XU WENXIN (CN)
FANG XUEFEI (CN)
XU DEYU (CN)
DING LIEMING (CN)

PCT/CN2022/110423

February 09, 2023

August 05, 2022

Click for automatic bibliography generation  

BETTA PHARMACEUTICALS CO LTD (CN)

A61P35/00; A61K39/395; A61K47/68; C07K16/28; C07K19/00; C12N15/13; C12N15/62

WO2019158113A1

2019-08-22

CN112409483A	2021-02-26
CN107686520A	2018-02-13
CN109265548A	2019-01-25
CN110003333A	2019-07-12
CN111433224A	2020-07-17
US20190177416A1	2019-06-13

EHRENMANN F.KAAS QLEFRANC M.-P., NUCLEIC ACIDS RES., vol. 38, 2010, pages D301 - D307
EHRENMANN, F.LEFRANC, M.-P., COLD SPRING HARBOR PROTOC., vol. 6, 2011, pages 737 - 749
"Sequences of Proteins of Immunological Interest", 1983, U.S.DEPT. OF HEALTH AND HUMAN SERVIES
J. MOL. BIOL., vol. 196, 1987, pages 901 - 917

View/Download PDF      PDF Help

Previous Patent: WIRELESS COMMUNICATION METHOD AND APPARATUS

Next Patent: TUMOR EVALUATION METHOD AND APPLICATION